Cell and Gene Therapy Manufacturing Services Market
Global Cell and Gene Therapy Manufacturing Services Market Size, Share & Trends Analysis Report, By Therapy (Cell Therapy and Gene Therapy) By Scale (Pre-commercial/ R&D Scale Manufacturing, Commercial-Scale Manufacturing), By Indication (Cancer, CVD, Orthopedic, Infectious Diseases, and Others) By End-User (Pharmaceutical and Biotechnology Companies, and Academic and Research Institutes) Forecast Period, 2021-2027
The global cell and gene therapy manufacturing services market is projected to grow at a CAGR of nearly 11.5% during the forecast period (2021-2027). The primary factor driving the market growth is the rise in the incidence of chronic diseases and R&D investments by companies and contract development and manufacturing organizations (CDMOs) for the expansion of clinical trials. As per the World Health Organization (WHO), the number of mortalitiues reported due to cancer was 10 million in 2020. The most common types of cancer in terms of new cancer incidences is breast, lung, colon and rectum, prostate, skin, and stomach.
In 2020, breast cancer accounted for 2.3 million new incidences, lung cancer with 2.2 million cases, and colon and rectum cancer with 1.9 million incidences, respectively. This has resulted an increased demand for cell and gene therapy for the treatment of cancer patients. Gene therapy supports to alter the abnormal functioning of cancer cells and therefore, it is being increasingly adopted for cancer therapeutics, which, in turn, is driving the demand for cell and gene therapy manufacturing services. However, high cost associated with the operation of cell and gene therapy manufacturing is hindering the growth of the market.
Impact of COVID-19 Pandemic on Global Cell and Gene Therapy Manufacturing Services Market
An increased R&D for cell-based therapies to treat COVID-19 patients have been reported. However, the trials for respiratory disease, oncology, ID/anti-infective, and cardiovascular disease were worse hit during the pandemic. The pandemic affected manufacturers and production units of cell and gene therapy manufacturing services due to lockdown, and travel restrictions which led to disruptions in the supply chain.
Segmental Outlook
The market is segmented based on therapy, scale, workflow, and end-user. Based on therapy, the market is segmented into cell and gene therapy. Among, therapy, the cell therapy segment is expected to grow at a decent rate during the forecast period. The attributable factor for the growth of the segment is increasing awareness about cell therapy coupled with the development of genomics methods for cell analysis. Based on the scale, the market is segmented into pre-commercial/ R&D scale manufacturing, and commercial-scale manufacturing. Among scale, pre-commercial/ R&D scale manufacturing holds a lucrative share in the market during the forecast period owing to the expansion of cell and gene pipelines across the globe. Based on indication, the market is segmented into cancer, CVD, orthopedic, infectious diseases, and others. Based on end-user, the market is segmented into pharmaceutical and biotechnology companies and academic and research institutes. Among end-user, the pharmaceutical and biotechnology companies segment is expected to grow at a decent rate during the forecast period. The attributable factor for the growth of the segment is increasing R&D expenditure by the companies in the sector coupled with rising collaborations between pharmaceutical and biotechnology companies.
Global Cell and Gene Therapy Manufacturing Services Market Share by Indication, 2020 (%)
Cell and Gene Therapy Manufacturing Services is Significantly Used for Cancer Therapeutics
Rising cancer incidences has resulted an increased demand for novel cell and gene therapy, which in turn, is propelling the market growth. Owing to the rising demand for cancer therapies, the biopharmaceutical firms are expanding their manufacturing base by using some strategic initiatives, such as mergers and acquisitions, and partnerships and collaborations. For instance, in July 2021, BioNTech SE and Kite, a Gilead Company signed a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, Maryland, US. The acquired Gaithersburg facility will offer manufacturing capacity to support clinical trials in the US. In addition, this will complement existing cell therapy manufacturing facility of BioNTech in Germany. This acquisition will support the development of widening pipeline of novel cell therapies of BioNTech, which includes product candidates for cancer based on its NEOSTIM and CAR-T Cell amplifying mRNA vaccine (CARVac) platforms and newly acquired individualized neoantigen TCR program.
Regional Outlook
The global cell and gene therapy manufacturing services market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is expected to hold a potential share during the forecast period. China, India, Japan, and the Rest of the Asia-Pacific are the major economies primarily contributing to the growth of the cell and gene therapy manufacturing services market in the region. The regional growth of the market is accredited to the rising incidence of cancer in the economies such as China and India. In addition, the rising production base of major biopharmaceutical firms is also contributing to the growth of the market. In 2020, North America held a major position in the market owing to the largest share in the biopharmaceutical sector and significant funding for R&D in biotechnology industry.
Global Cell and Gene Therapy Manufacturing Services Market Growth, by Region 2021-2027
Asia- Pacific is Projected to Hold Considerable Share in the Market During the Forecast Period
Asia-Pacific is anticipated to hold potential share in the market. In the region, China and India are showing progress in the market. The rising geriatric population, rising incidence of colorectal cancer are the factors that are driving the growth of the market in the region. As per the report of WHO, in 2020, in the Asia-pacific region, around 569,186 incidences of colon cancer were recorded, which is 49.6% of total cases across the globe.
Market Players Outlook
Some prominent players in the market include Thermo Fisher Inc, Merck KGaA, and Lonza Group Ltd., and among others. The market players are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, and many others to thrive in a competitive environment. For instance, in June 2021, CDMO Yposkesi announced its plans to build a second commercial gene and cell therapy manufacturing plant.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cell and gene therapy manufacturing services market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Cell and Gene Therapy Manufacturing Services Industry
• Recovery Scenario of Global Cell and Gene Therapy Manufacturing Services Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Conclusion
2.3. Porter’s Analysis
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Thermo Fisher Scientific Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.2. Merck KGaA
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.3. Lonza Group Ltd.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Cell and Gene Therapy Manufacturing Services Market by Therapy
5.1.1. Cell Therapy
5.1.2. Gene Therapy
5.2. Global Cell and Gene Therapy Manufacturing Services Market by Scale
5.2.1. Pre-commercial/ R&D Scale Manufacturing
5.2.2. Commercial Scale Manufacturing
5.3. Global Cell and Gene Therapy Manufacturing Services Market by Indication
5.3.1. Cancer
5.3.2. CVD
5.3.3. Orthopedic
5.3.4. Infectious Diseases
5.3.5. Others
5.4. Global Cell and Gene Therapy Manufacturing Services Market by End User
5.4.1. Pharmaceutical and Biotechnology Companies
5.4.2. Academic and Research Institutes
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. bluebird bio, Inc.
7.2. Boehringer Ingelheim International GmbH
7.3. Catalent, Inc.
7.4. Cell and Gene Therapy Catapult
7.5. Innovative Cellular Therapeutics Co., Ltd.
7.6. Charles River Laboratories International, Inc.
7.7. F. Hoffmann-La Roche Ltd.
7.8. FUJIFILM Holdings Corp.
7.9. Miltenyi Biotec B.V. & Co. KG
7.10. Nikon CeLL innovation Co., Ltd.
7.11. Novartis AG
7.12. Oxford Biomedica plc
7.13. Samsung Biologics
7.14. Takara Bio Inc.
7.15. WuXi AppTec Co., Ltd.
1. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
2. GLOBAL CELL THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
3. GLOBAL GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY SCALE, 2020-2027 ($ MILLION)
5. GLOBAL PRECOMMERCIAL/ R&D SCALE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL COMMERCIAL-SCALE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
8. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES FOR CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES FOR CVD MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES FOR ORTHOPEDIC MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES FOR INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES FOR OTHER INDICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
14. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES FOR ACADEMIC AND RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
16. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
17. NORTH AMERICAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
18. NORTH AMERICAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
19. NORTH AMERICAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY SCALE, 2020-2027 ($ MILLION)
20. NORTH AMERICAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
21. NORTH AMERICAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
22. EUROPEAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
23. EUROPEAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
24. EUROPEAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY SCALE, 2020-2027 ($ MILLION)
25. EUROPEAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
26. EUROPEAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
27. ASIA-PACIFIC CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
28. ASIA-PACIFIC CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
29. ASIA-PACIFIC CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY SCALE, 2020-2027 ($ MILLION)
30. ASIA-PACIFIC CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
31. ASIA-PACIFIC CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
32. REST OF THE WORLD CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
33. REST OF THE WORLD CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY SCALE, 2020-2027 ($ MILLION)
34. REST OF THE WORLD CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
35. REST OF THE WORLD CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET, 2020-2027 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET BY SEGMENT, 2020-2027 ($ MILLION)
3. RECOVERY OF GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET, 2021-2027(%)
4. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY THERAPY, 2020 VS 2027 (%)
5. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY SCALE, 2020 VS 2027 (%)
6. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY INDICATION, 2020 VS 2027 (%)
7. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY END-USER, 2020 VS 2027 (%)
8. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
9. GLOBAL CELL THERAPY MANUFACTURING SERVICES MARKET SHARE BY REGION, 2020 VS 2027 (%)
10. GLOBAL GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY REGION, 2020 VS 2027 (%)
11. GLOBAL PRE-COMMERCIAL/ R&D SCALE MANUFACTURING CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY REGION, 2020 VS 2027 (%)
12. GLOBAL COMMERCIAL-SCALE MANUFACTURING CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY REGION, 2020 VS 2027 (%)
13. GLOBAL CELL PROCESSING MANUFACTURING SERVICES MARKET SHARE BY REGION, 2020 VS 2027 (%)
14. GLOBAL CELL BANKING CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY REGION, 2020 VS 2027 (%)
15. GLOBAL PROCESS DEVELOPMENT IN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY REGION, 2020 VS 2027 (%)
16. GLOBAL VECTOR PRODUCTION IN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY REGION, 2020 VS 2027 (%)
17. GLOBAL OTHERS (RAW MATERIAL TESTING) CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SHARE BY REGION, 2020 VS 2027 (%)
18. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SHARE BY REGION, 2020 VS 2027 (%)
19. GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES FOR ACADEMIC AND RESEARCH INSTITUTES MARKET SHARE BY REGION, 2020 VS 2027 (%)
20. US CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
21. CANADA CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
22. UK CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
23. FRANCE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
24. GERMANY CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
25. ITALY CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
26. SPAIN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
27. ROE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
28. INDIA CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
29. CHINA CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
30. JAPAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
31. ASEAN CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
32. SOUTH KOREA CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
33. REST OF ASIA-PACIFIC CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
34. REST OF THE WORLD CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2020-2027 ($ MILLION)
